- Trials with a EudraCT protocol (137)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
137 result(s) found for: Cytarabine .
Displaying page 1 of 7.
| EudraCT Number: 2015-004896-60 | Sponsor Protocol Number: LUMC2015-02 | Start Date*: 2015-11-26 |
| Sponsor Name:Leiden University Medical Center | ||
| Full Title: Decitabine-cytarabine chemotherapy in elderly AML and high risk MDS patients (> 65 years) with high early mortality risk | ||
| Medical condition: Acute myeloid leukemia and high risk myelodysplasia | ||
| Disease: | ||
| Population Age: Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-000344-42 | Sponsor Protocol Number: AG-221-AML-004 | Start Date*: 2016-01-21 | ||||||||||||||||
| Sponsor Name:Celgene Corporation | ||||||||||||||||||
| Full Title: A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemi... | ||||||||||||||||||
| Medical condition: Treatment of subjects 60 years or older with acute myeloid leukemia (AML) refractory to or relapsed after second- or third-line AML therapy and positive for an isocitrate dehydrogenase 2 (IDH2) mut... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Ongoing) GB (Ongoing) ES (Ongoing) DK (Ongoing) BE (Ongoing) AT (Ongoing) CZ (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2014-001233-89 | Sponsor Protocol Number: SGI-110-04 | Start Date*: 2015-05-15 | |||||||||||
| Sponsor Name:Astex Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for I... | |||||||||||||
| Medical condition: Acute Myeloid Leukemia (AML) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) SE (Ongoing) BE (Ongoing) HU (Ongoing) DE (Ongoing) GB (Ongoing) NL (Ongoing) FI (Ongoing) CZ (Completed) AT (Ongoing) ES (Ongoing) PL (Ongoing) FR (Ongoing) DK (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-002822-19 | Sponsor Protocol Number: B1371019 | Start Date*: 2018-07-09 | |||||||||||
| Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
| Full Title: A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN ... | |||||||||||||
| Medical condition: ACUTE MYELOID LEUKEMIA | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Ongoing) CZ (Ongoing) SE (Ongoing) HU (Ongoing) PL (Ongoing) ES (Ongoing) DE (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-003065-15 | Sponsor Protocol Number: WO29519 | Start Date*: 2015-12-15 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE III STUDY OF IDASANUTLIN, AN MDM2 ANTAGONIST, WITH CYTARABINE VERSUS CYTARABINE PLUS PLACEBO IN PATIENTS WITH RELAPSED OR REFRACTO... | |||||||||||||
| Medical condition: Relapsed or refractory acute myeloid leukemia (AML). | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Ongoing) FI (Ongoing) GB (Ongoing) NO (Ongoing) BE (Ongoing) NL (Ongoing) ES (Ongoing) FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-002345-39 | Sponsor Protocol Number: Göteborg University | Start Date*: 2006-02-16 |
| Sponsor Name:NOPHO NHL-group | ||
| Full Title: B-NHL BFM 04 | ||
| Medical condition: B-cell lymphoma or B-ALL in children up to 18 years of age | ||
| Disease: | ||
| Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: SE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-000319-15 | Sponsor Protocol Number: FLUGAZA | Start Date*: 2014-07-25 | |||||||||||
| Sponsor Name:Fundación PETHEMA | |||||||||||||
| Full Title: A phase III, multicentre, randomized, open label clinical trial comparing azacytidine (Vidaza®) versus fludarabine plus cytarabine in elderly patients with newly diagnosed acute myeloid leukemia. | |||||||||||||
| Medical condition: Newly diagnosed acute myeloid leukemia. | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-023691-33 | Sponsor Protocol Number: MUV-MEMMAT-01 | Start Date*: 2011-05-05 |
| Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Kinder- und Jugendheilkunde | ||
| Full Title: A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma | ||
| Medical condition: Recurrent/progressive medulloblastoma | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: AT (Ongoing) SE (Restarted) CZ (Ongoing) DK (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2011-001086-41 | Sponsor Protocol Number: UKM10_0014 | Start Date*: 2012-02-28 | |||||||||||
| Sponsor Name:University Hospital of Muenster | |||||||||||||
| Full Title: A randomized, placebo-controlled, multi-center phase I/II trial to assess the safety and efficacy of nintedanib (BIBF 1120) added to low-dose cytarabine in elderly patients with AML unfit for an in... | |||||||||||||
| Medical condition: untreated acute myeloid leukemia patients unfit for an intensive treatment | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-005794-29 | Sponsor Protocol Number: GFM-BAR-C-2005 | Start Date*: 2006-03-30 |
| Sponsor Name:Groupe français des Myélodysplasies | ||
| Full Title: Traitement des syndromes myélodysplasiques par l'association aracytine et bortezomib | ||
| Medical condition: Myelodysplastic syndrome (MDS) is a clonal disease of the bone marrow stem cells. The disease is frequently associated with cytopenia and/or blastosis. An evolution to an acute leukemia is not unfr... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2012-001891-13 | Sponsor Protocol Number: LeMLAR | Start Date*: 2012-12-17 |
| Sponsor Name:University Hospital Essen | ||
| Full Title: Lenalidomide in conjunction with methotrexate, leucovorin, cytarabine and rituximab for the treatment of relapsed or refractory CD20-positive aggressive lymphomas: an open-label, multicenter phase ... | ||
| Medical condition: Relapsed or refractory CD20-positive aggressive B-cell lymphomas | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-001076-38 | Sponsor Protocol Number: GMI-1271-301 | Start Date*: 2018-12-21 | |||||||||||
| Sponsor Name:GlycoMimetics, Inc. | |||||||||||||
| Full Title: A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia | |||||||||||||
| Medical condition: Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IE (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-000699-24 | Sponsor Protocol Number: PHRC2010-03 | Start Date*: 2014-10-02 |
| Sponsor Name:CHU Angers-DAMR | ||
| Full Title: Essai de phase 3 visant à améliorer la survie globale des LAM de l’adulte de 18 à 60 ans en comparant l’idarubicine à forte dose à la daunorubicine à l’induction, la cytarabine à haute-dose et à do... | ||
| Medical condition: Leucémie aiguë myéloïde | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: FR (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-003031-19 | Sponsor Protocol Number: IELSG42 | Start Date*: 2014-12-15 |
| Sponsor Name:IELSG (INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP) | ||
| Full Title: An international phase II trial assessing tolerability and efficacy of sequential Methotrexate-Aracytin-based combination and R-ICE combination, followed by high-dose chemotherapy supported by auto... | ||
| Medical condition: systemic diffuse large B-cell lymphoma with central nervous system involvement at diagnosis or relapse | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: IT (Ongoing) NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-003081-18 | Sponsor Protocol Number: BRD/07/137 | Start Date*: 2008-09-29 |
| Sponsor Name:University College Hospital | ||
| Full Title: Phase II study of low intensity allogeneic transplantation in Mantle Cell Lymphoma | ||
| Medical condition: Mantle Cell Lymphoma (MCL) is an increasingly recognised yet rare sub-type of non-hodgkin's Lymphoma (NHL), representing between 5 and 8% of all cases. Typically a disease of the elderly with a me... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2009-014462-26 | Sponsor Protocol Number: DB-AML-01 | Start Date*: 2010-05-04 | |||||||||||
| Sponsor Name:Ghent University Hospital | |||||||||||||
| Full Title: Dutch-Belgian pediatric AML protocol for children with newly diagnosed acute myeloid leukemia, based on the NOPHO-AML 2004 study | |||||||||||||
| Medical condition: Acute Myeloid Leukemia in children | |||||||||||||
|
|||||||||||||
| Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2004-004321-95 | Sponsor Protocol Number: AMLSG 07-04 | Start Date*: 2005-05-26 |
| Sponsor Name:University of Ulm | ||
| Full Title: RANDOMIZED PHASE II-STUDY ON VALPROIC ACID, ALL-TRANS RETINOIC ACID AND THEIR COMBINATION IN INDUCTION AND CONSOLIDATION THERAPY AS WELL AS PEGFILGRASTIM AFTER CONSOLIDATION THERAPY IN YOUNGER PATI... | ||
| Medical condition: newly diagnosed acute myeloid leukemia | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: AT (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-002823-15 | Sponsor Protocol Number: 1968 | Start Date*: 2005-10-25 |
| Sponsor Name:Nottingham University Hospitals NHS Trust | ||
| Full Title: A PHASE I/II TRIAL OF THE USE OF SIROLIMUS (RAPAMUNE) AND LOW DOSE ARA-C IN OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA (AML) | ||
| Medical condition: Acute myeloid leukaemia (AML) and high risk myelodysplasia (MDS) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Ongoing) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-000140-42 | Sponsor Protocol Number: 2215-CL-0301 | Start Date*: 2016-04-20 | |||||||||||
| Sponsor Name:Astellas Pharma Global Development, Inc. (APGD) | |||||||||||||
| Full Title: A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation | |||||||||||||
| Medical condition: Relapsed or Refractory Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Ongoing) GB (Ongoing) BE (Ongoing) ES (Ongoing) IE (Ongoing) FR (Ongoing) PL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-004890-28 | Sponsor Protocol Number: AC220-007 | Start Date*: 2014-06-18 | |||||||||||
| Sponsor Name:Daiichi Sankyo Inc | |||||||||||||
| Full Title: A Phase 3 Open-Label Randomized Study of Quizartinib Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-li... | |||||||||||||
| Medical condition: Refractory or Relapsed FLT3-ITD Positive Acute Myeloid Leukemia (AML) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Ongoing) DE (Ongoing) IT (Ongoing) NL (Ongoing) ES (Ongoing) BE (Ongoing) HU (Ongoing) CZ (Ongoing) HR (Ongoing) PL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
